Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells 30,000 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 30,000 shares of TransMedics Group stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $130.07, for a total transaction of $3,902,100.00. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,017,905.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

TransMedics Group Price Performance

TransMedics Group stock opened at $128.77 on Friday. The company has a market cap of $4.24 billion, a price-to-earnings ratio of -378.74 and a beta of 1.87. The firm’s fifty day moving average is $89.25 and its 200 day moving average is $79.26. The company has a quick ratio of 8.76, a current ratio of 9.72 and a debt-to-equity ratio of 3.18. TransMedics Group, Inc. has a 52-week low of $36.42 and a 52-week high of $132.96.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 7.95%. The company had revenue of $96.90 million for the quarter, compared to the consensus estimate of $83.78 million. During the same quarter in the prior year, the firm earned ($0.08) earnings per share. TransMedics Group’s revenue was up 132.9% on a year-over-year basis. Sell-side analysts forecast that TransMedics Group, Inc. will post 0.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Blair William & Co. IL increased its position in TransMedics Group by 15.3% during the first quarter. Blair William & Co. IL now owns 183,524 shares of the company’s stock valued at $13,570,000 after acquiring an additional 24,417 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in TransMedics Group by 8.6% during the first quarter. State Board of Administration of Florida Retirement System now owns 9,843 shares of the company’s stock valued at $745,000 after acquiring an additional 780 shares during the last quarter. Entropy Technologies LP bought a new position in TransMedics Group during the first quarter valued at $201,000. ProShare Advisors LLC increased its position in TransMedics Group by 7.8% during the first quarter. ProShare Advisors LLC now owns 5,871 shares of the company’s stock valued at $434,000 after acquiring an additional 427 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its position in TransMedics Group by 337,462.5% during the first quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock valued at $1,997,000 after acquiring an additional 26,997 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

TMDX has been the subject of a number of research analyst reports. Oppenheimer lifted their price target on shares of TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 1st. Morgan Stanley lifted their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. boosted their target price on shares of TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. TD Cowen boosted their target price on shares of TransMedics Group from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Finally, Canaccord Genuity Group boosted their target price on shares of TransMedics Group from $102.00 to $117.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $119.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.